Back to Search Start Over

CD4 + T Cell Responses to Toxoplasma gondii Are a Double-Edged Sword.

Authors :
El Bissati, Kamal
Krishack, Paulette A.
Zhou, Ying
Weber, Christopher R.
Lykins, Joseph
Jankovic, Dragana
Edelblum, Karen L.
Fraczek, Laura
Grover, Harshita
Chentoufi, Aziz A.
Singh, Gurminder
Reardon, Catherine
Dubey, J. P.
Reed, Steve
Alexander, Jeff
Sidney, John
Sette, Alessandro
Shastri, Nilabh
McLeod, Rima
Source :
Vaccines; Sep2023, Vol. 11 Issue 9, p1485, 18p
Publication Year :
2023

Abstract

CD4<superscript>+</superscript> T cells have been found to play critical roles in the control of both acute and chronic Toxoplasma infection. Previous studies identified a protective role for the Toxoplasma CD4<superscript>+</superscript> T cell-eliciting peptide AS15 (AVEIHRPVPGTAPPS) in C57BL/6J mice. Herein, we found that immunizing mice with AS15 combined with GLA-SE, a TLR-4 agonist in emulsion adjuvant, can be either helpful in protecting male and female mice at early stages against Type I and Type II Toxoplasma parasites or harmful (lethal with intestinal, hepatic, and spleen pathology associated with a storm of IL6). Introducing the universal CD4<superscript>+</superscript> T cell epitope PADRE abrogates the harmful phenotype of AS15. Our findings demonstrate quantitative and qualitative features of an effective Toxoplasma-specific CD4<superscript>+</superscript> T cell response that should be considered in testing next-generation vaccines against toxoplasmosis. Our results also are cautionary that individual vaccine constituents can cause severe harm depending on the company they keep. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
2076393X
Volume :
11
Issue :
9
Database :
Complementary Index
Journal :
Vaccines
Publication Type :
Academic Journal
Accession number :
172752138
Full Text :
https://doi.org/10.3390/vaccines11091485